China’s drug regulator clears mpox vaccine; to undergo clinical trial
Beijing, Sep 10: China’s top drug regulator has cleared a mpox vaccine developed by local drug firm Sinopharm for clinical trials which could be the country’s first experimental dose to battle the deadly disease.
The domestic vaccine candidate, created by the Shanghai Institute of Biological Products and administered by Sinopharm, is expected to play an important role in preventing and controlling mpox infections, the company said in a statement released on Monday afternoon.
There is currently no approved mpox vaccine in China. Globally, a few vaccines have been approved in the United States, Canada, the European Union, Japan and Russia.
In China, a vaccine candidate typically goes through three phases of clinical trials before gaining market approval.
The process can take years, even decades. However, the National Medical Products Administration, China's top drug regulator, has launched a number of accelerated or streamlined channels to facilitate applications of novel drugs and vaccines or those in urgent need, state-run China Daily reported on Tuesday.
According to the company, the new vaccine is a replication-deficient vaccine based on a strain called MVA.
The description is the same as Jynneos, the world's first mpox vaccine approved by the Food and Drug Administration in the United States in 2019.
The World Health Organisation said on August 14 that the mpox outbreak in Africa constitutes a public health emergency of international concern — its highest form of alert.
Previously, in July 2022, the WHO declared a global emergency but then lifted it in May last year because of a sustained decline in international cases.
So far, more than 120 countries and regions across the world have reported more than 100,000 confirmed infections and 226 related deaths.
China reported its first imported case in September 2022 and the first domestic case in June last year.
By the end of July, the nation had reported 2,567 confirmed cases, according to the China Daily report.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Two more infants die, toll in Jhansi medical college fire rises to 17
Jhansi (UP) (PTI): Two more infants rescued from a fire that ripped through the Maharani Laxmi Bai Medical College here have died, taking the total toll in the blaze to 17, a senior official said on Sunday.
Thirty-nine newborns were rescued from a devastating fire in the medical college hospital's neonatal intensive care unit on the night of November 15.
Dr Narendra Singh Sengar, the medical college's principal, told PTI that of the 39 infants rescued, two more died on Saturday.
While 10 babies died on the night of the fire, the remainder succumbed to their "illnesses", he said.
A post-mortem of the two bodies was done on Saturday and the cause of death was confirmed as "illness" in both cases. The bodies have been handed over to the family members, Sengar said.
The birth weight of both infants was 800 grams and one of them also had a hole in the heart, he added.
Meanwhile, Congress sources said on Sunday that the party's state chief Ajay Rai and Barabanki MP Tanuj Punia would travel to Jhansi and visit the medical college. They will also meet the families whose babies died in the fire.
